BRPI0821176A2 - phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex - Google Patents

phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex

Info

Publication number
BRPI0821176A2
BRPI0821176A2 BRPI0821176A BRPI0821176A BRPI0821176A2 BR PI0821176 A2 BRPI0821176 A2 BR PI0821176A2 BR PI0821176 A BRPI0821176 A BR PI0821176A BR PI0821176 A BRPI0821176 A BR PI0821176A BR PI0821176 A2 BRPI0821176 A2 BR PI0821176A2
Authority
BR
Brazil
Prior art keywords
disease
condition
complex
syndrome
patient presenting
Prior art date
Application number
BRPI0821176A
Other languages
Portuguese (pt)
Inventor
Lakmal Boteju
Paul Bingham
Rajinder Bhasin
Robert Rodriguez
Robert Shorr
Zuzana Zachar
Original Assignee
Robert Rodriguez
Robert Shorr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert Rodriguez, Robert Shorr filed Critical Robert Rodriguez
Publication of BRPI0821176A2 publication Critical patent/BRPI0821176A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0821176A 2008-03-04 2008-03-04 phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex BRPI0821176A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/002853 WO2009110859A1 (en) 2008-03-04 2008-03-04 Modulation of enzymatic structure, activity, and/or expression level

Publications (1)

Publication Number Publication Date
BRPI0821176A2 true BRPI0821176A2 (en) 2015-10-06

Family

ID=41056265

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821176A BRPI0821176A2 (en) 2008-03-04 2008-03-04 phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex

Country Status (10)

Country Link
EP (1) EP2260019A4 (en)
JP (1) JP2011513395A (en)
KR (1) KR20110004846A (en)
CN (1) CN102089276A (en)
AU (1) AU2008352076A1 (en)
BR (1) BRPI0821176A2 (en)
CA (1) CA2717511A1 (en)
IL (1) IL207943A0 (en)
MX (1) MX2010009673A (en)
WO (1) WO2009110859A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263653B2 (en) 2007-04-18 2012-09-11 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
CN102056605A (en) * 2008-04-04 2011-05-11 罗伯特·绍尔 Pharmaceutical composition
AU2014398232B2 (en) 2014-06-19 2019-11-28 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
WO2015195071A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
JP2022514084A (en) * 2018-12-20 2022-02-09 ラファエル ファーマシューティカルズ， インコーポレイテッド Oral therapy with 6,8-bis-benzylthio-octanoic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463093A (en) * 1993-11-26 1995-10-31 Garnett; Merrill Palladium complexes and methods for using same in the treatment of tumors or Psoriasis
DE4343593C2 (en) * 1993-12-21 1998-05-20 Asta Medica Ag Use of R - (+) - alpha-lipoic acid, R - (-) - dihydrolipoic acid or the metabolites as well as their salts, esters, amides for the treatment of compensated and decompensated insulin resistance
BR9914789A (en) * 1998-10-26 2001-10-02 Univ New York State Res Found Lipoic acid derivatives and their uses in the treatment of disease
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
IT1312060B1 (en) * 1999-04-09 2002-04-04 Antibioticos Spa USE OF ALPHA LIPOIC ACID IN ANTIMETASTATIC TREATMENT.
EP1172110A3 (en) * 2000-07-07 2003-09-17 Basf Aktiengesellschaft Use of lipoic acid as a bioavailaty enhancer of mineral salts
US20020071234A1 (en) * 2000-10-25 2002-06-13 George Alexanian Battery powered programmable remote switch controller
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
ES2528414T3 (en) * 2007-04-18 2015-02-10 Cornerstone Pharmaceuticals, Inc. Pharmaceutical formulations containing lipoic acid derivatives
KR101644192B1 (en) * 2007-04-18 2016-07-29 코너스톤 파마슈티칼스, 인크. Lipoic acid derivatives

Also Published As

Publication number Publication date
IL207943A0 (en) 2010-12-30
EP2260019A4 (en) 2011-08-03
WO2009110859A1 (en) 2009-09-11
MX2010009673A (en) 2011-03-15
CN102089276A (en) 2011-06-08
CA2717511A1 (en) 2009-09-11
KR20110004846A (en) 2011-01-14
JP2011513395A (en) 2011-04-28
EP2260019A1 (en) 2010-12-15
AU2008352076A1 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
BRPI0821176A2 (en) phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex
Vieta et al. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients
BRPI0815308A2 (en) lagerhans islet peptide, pharmaceutical composition, method for stimulating islet neogenesis or stimulating langerhans islet regeneration and method for treating a condition associated with defective pancreatic function in an individual
BRPI0510224A (en) autoimmune disease prevention methods and industrialized article
WO2012018535A3 (en) Wellness panel
BRPI0717697A2 (en) compound, pharmaceutical composition, use of the compound, method of treating a patient suffering from a pathological condition or disease and combination of products
BRPI0906549A2 (en) Medical bandages with valves and kits containing them.
ES2572372T3 (en) Diagnostic method of neurodegenerative diseases based on the measurement of levels or activity of SIRT1
BR112014009223A2 (en) method for the diagnosis of niemann-pick disease
BRPI0805268A2 (en) absorbent article including an absorbent layer having a plurality of spaced beam elements
WO2007061755A3 (en) Systems and methods to assess one or more body fluid metrics
BRPI0910608A2 (en) methods and systems for evaluating clinical outcomes
BR112012028452A2 (en) Devices and methods for assessing changes in corneal health
BRPI0821894A2 (en) Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof
BRPI0912842A8 (en) pharmaceutical composition, methods to prevent or treat niacin-induced flushing in an individual, to reduce at least one niacin therapy-related flushing symptom in an individual, to decrease protaglandin-related side effects in an individual, to decrease a rate of discontinuation of niacin treatment by an individual, to increase patient compliance with niacin treatment, to treat atherosclerosis in a patient, to treat a disease related to a low hdl profile in a patient, nicotinic acid formulation of modified dispensing, pharmaceutical composition use, and aspirin microcapsule
BRPI0914925A2 (en) cyclic peptide, use of a peptide, methods for producing a cyclic peptide and for diagnosing a disease or condition, and antibody
BR112013017314A2 (en) compositions comprising sodium glucose co-transporter 1 and 2 inhibitors and methods of use
WO2010045490A3 (en) Human biomarker hypermapping for depressive disorders
BRPI0917616A2 (en) Arrangement for measuring the local velocity of a liquid containing a magnetic material in a vein within a region of action, Method for measuring the local velocity of a liquid containing a magnetic material in a vein within a region of action computer
BR112014013273A2 (en) dental superstructures and bridges and methods for their manufacture
WO2008117027A3 (en) Altered mitochondrial activity in diseases resulting from oxidative stress
NI201100183A (en) CCR3 ANTAGONISTS OF ARYLSULFONAMIDE 2,5 - DISUSTITUTED
BR102013030918A8 (en) brake caliper assembly with a spacer tape and a manufacturing method
BR112017027304A2 (en) method for the diagnosis of farber's disease
BRPI0814672A2 (en) METHOD OF TREATING A PATIENT, AND POST-TRAUMATIC STRESS DISTURBANCE, AND METHODS FOR IMPROVING RESILIENCE IN A PATIENT AND DIAGNOSING DIAGNOSIS IN A PATIENT.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]